biostudies-literatureUnknown24(8)Verheye SElixir Medical Corporation<h4>Background</h4>The DynamX Novolimus-Eluting Coronary Bioadaptor System ( DynamX ® Bioadaptor) has uncaging elements that disengage after the resorption of the polymer coating, aiming to restore vessel function in the treated segment and to avoid long-term adverse outcomes associated with the permanent caging of the coronary artery seen with conventional stenting.<h4>Methods</h4>This prospective, multicenter, single-arm first-in-human study enrolled 50 patients in Belgium and Italy who were treated with the DynamX Bioadaptor. Eligible patients had <i>de novo</i> lesions in coronary arteries measuring between 2.5 and 3.5 mm in diameter and ≤ 24 mm in length. Clinical follow-up was performed up to 36 months. This analysis includes the intention-to-treat population and is based on data avReviews in cardiovascular medicine221https://www.ebi.ac.uk/biostudies/studies/S-EPMC11266769biostudies-literatureFinal 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary Bioadaptor System and Supporting Preclinical Data.PMC11266769De Bruyne BAbizaid AGiannini FVerheye SCosta RAColombo ABedogni FDubois CCosta JRVrolix MMontorfano MChamie DfalseFinal 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary Bioadaptor System and Supporting Preclinical Data.<h4>Background</h4>The DynamX Novolimus-Eluting Coronary Bioadaptor System ( DynamX ® Bioadaptor) has uncaging elements that disengage after the resorption of the polymer coating, aiming to restore vessel function in the treated segment and to avoid long-term adverse outcomes associated with the permanent caging of the coronary artery seen with conventional stenting.<h4>Methods</h4>This prospective, multicenter, single-arm first-in-human study enrolled 50 patients in Belgium and Italy who were treated with the DynamX Bioadaptor. Eligible patients had <i>de novo</i> lesions in coronary arteries measuring between 2.5 and 3.5 mm in diameter and ≤ 24 mm in length. Clinical follow-up was performed up to 36 months. This analysis includes the intention-to-treat population and is based on data av2023-01-01T00:00:00Z2023 Aug2026-06-01T07:41:46.06Z2026-04-08T10:34:30.341ZS-EPMC112667693907670310.31083/j.rcm2408221